|
paxil voucher cr ABITRIL dosing recommendations in current labeling for treatment of epilepsy were based on use in patients with partial seizures 12 years of age and older paxil voucher cr, most of whom were taking enzyme-inducing antiepileptic drugs (AEDs; e.g. paxil voucher cr, carbamazepine paxil voucher cr, phenytoin paxil voucher cr, primidone paxil voucher cr, and phenobarbital) which lower plasma levels of GABITRIL by inducing its metabolism. Use of GABITRIL without enzyme-inducing antiepileptic drugs result in blood levels about twice those attained in the studies on which current dosing recommendations are based (see DOSAGE AND ADMINISTRATION). Safety and effectiveness of GABITRIL have not been established for any indication other than as adjunctive paxil voucher cr.
paxil voucher cr therapy for partial seizures in adults and children 12 years and older. In nonepileptic patients who develop seizures while on GABITRIL treatment paxil voucher cr, GABITRIL should be discontinued and patients should be evaluated for an underlying seizure disorder. Seizures and status epilepticus are known to occur with GABITRIL overdosage (see OVERDOSAGE). Other changes to the label can be found in the PHARMACOKINETICS paxil voucher cr, ADVERSE REACTIONS paxil voucher cr, OVERDOSAGE paxil voucher cr, and DOSAGE AND ADMINISTRATION sections of the label. GABITRIL is approved for use only as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures. Because GABITRIL has not been systematically evaluated in adequate and well-controlled clinical trials for any other indication paxil voucher cr, its safety and effectiveness have not been established for any other use. Cephalon does not recommend the use of GABITRIL outside of its approved indication. Dosing guidelines for GABITRIL have been established only for its use as an adjunctive treatment for partial seizures and not for any other indication. The current dosing guidelines for GABITRIL have been established primarily for patients 12 years and older with partial epilepsy who are taking hepatic enzyme-inducing anticonvulsant drugs. Patients who are not taking enzyme-inducing drugs would have systemic exposu.
paxil voucher cr Cally evaluated in adequate and well-controlled clinical trials for any other indication paxil voucher cr, its safety and effectiveness have not been established for any other use. Cephalon does not recommend the use of GABITRIL outside of its approved indication. Dosing guidelines for GABITRIL have been established only for its use as an adjunctive treatment for partial seizures and not for any other indication. The current dosing guidelines for GABITRIL have been established primarily for patients 12 years and older with partial epilepsy who are taking hepatic enzyme-inducing anticonvulsant drugs. Patients who are not taking enzyme-inducing drugs would have systemic exposur.
paxil voucher cr 
paxil voucher cr | | | | | |
paxil voucher cr
|
